46,904 Shares in Genmab A/S (NASDAQ:GMAB) Purchased by Madison Investment Advisors LLC

Madison Investment Advisors LLC purchased a new position in shares of Genmab A/S (NASDAQ:GMAB) during the 4th quarter, HoldingsChannel reports. The institutional investor purchased 46,904 shares of the company’s stock, valued at approximately $979,000.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. raised its position in Genmab A/S by 10.3% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,891 shares of the company’s stock worth $186,000 after acquiring an additional 827 shares during the period. EverSource Wealth Advisors LLC raised its position in Genmab A/S by 295.3% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company’s stock worth $26,000 after acquiring an additional 939 shares during the period. Lindbrook Capital LLC raised its position in Genmab A/S by 105.4% in the fourth quarter. Lindbrook Capital LLC now owns 1,851 shares of the company’s stock worth $39,000 after acquiring an additional 950 shares during the period. GAMMA Investing LLC raised its position in Genmab A/S by 96.6% in the fourth quarter. GAMMA Investing LLC now owns 2,139 shares of the company’s stock worth $45,000 after acquiring an additional 1,051 shares during the period. Finally, Eagle Asset Management Inc. raised its position in shares of Genmab A/S by 10.0% in the third quarter. Eagle Asset Management Inc. now owns 12,356 shares of the company’s stock valued at $285,000 after purchasing an additional 1,121 shares during the period. 7.07% of the stock is currently owned by hedge funds and other institutional investors.

Genmab A/S Price Performance

GMAB stock opened at $19.76 on Friday. Genmab A/S has a one year low of $18.64 and a one year high of $31.02. The stock has a market cap of $13.08 billion, a PE ratio of 11.36, a P/E/G ratio of 2.65 and a beta of 0.98. The firm has a 50 day simple moving average of $21.04 and a two-hundred day simple moving average of $22.15.

Genmab A/S (NASDAQ:GMAB) last released its quarterly earnings results on Wednesday, February 12th. The company reported $0.57 EPS for the quarter, topping analysts’ consensus estimates of $0.28 by $0.29. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%. On average, research analysts expect that Genmab A/S will post 1.45 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently issued reports on GMAB shares. HC Wainwright reissued a “buy” rating and issued a $50.00 price target on shares of Genmab A/S in a research report on Thursday, January 23rd. William Blair raised shares of Genmab A/S from a “market perform” rating to an “outperform” rating in a research report on Tuesday, March 11th. Sanford C. Bernstein raised shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a research report on Friday, December 20th. Truist Financial lowered their price target on shares of Genmab A/S from $50.00 to $45.00 and set a “buy” rating on the stock in a research report on Tuesday, March 11th. Finally, Leerink Partnrs raised shares of Genmab A/S from a “hold” rating to a “strong-buy” rating in a research report on Thursday, February 13th. Four analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $41.33.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.